Malaria remains the leading cause of morbidity and mortality in Malawi with approximately six million episodes of malaria per year. It is endemic in 95% of the country, with 98% of infections due to Plasmodium falciparum. The Ministry of Health estimates that malaria accounts for 34% of all outpatient visits and 40% of all hospital admissions among children under five. Four out of ten hospital deaths are reported to be due to malaria.
With nearly $134 million in investment between 2006 and 2012, the USG’s Presidential Malaria Initiative (PMI) has contributed to substantial progress in scaling-up malaria prevention and control interventions. With FY 2012 funding, PMI:
Procured and distributed 1.26 million insecticide treated nets, 7.69 million artemisinin-based combination therapy doses and 2.96 million rapid diagnostic tests (RDTs). It also supported national scale up of RDT roll-out which began in 2011, reducing the high demand for Artemisinin Combination Therapy (ACT) by treating mainly confirmed malaria cases.
Sprayed 77,647 houses protecting 321,919 Malawians, and supported the training of 885 personnel on Indoor Residual Spray (IRS), 31 health workers on Intermittent Preventive Therapy in Pregnancy (IPTp), 1,039 on malaria diagnosis and 204 on treatment with ACT.
The program also strengthened intermittent preventive treatment for pregnant women through focused antenatal care and supportive supervision, and conducted entomological monitoring in seven IRS districts. PMI also supported the malaria indicator survey, impact evaluation and drug efficacy studies. PMI partnered with MoH in policy dialogue to ensure that the most recent evidence is translated into program implementation.
Towards Universal Access
Funding (FY 2013)
Government of Malawi, Chemonics, JHPIEGO, John Snow Inc., Johns Hopkins University, Population Services International, Malaria Alert Centre, MalariaCare, Abt. Associates
Miriam Lutz, Chief
Office of Health
Last updated: October 04, 2013